Skip to main content
SpringerLink
Log in

Management of Lupus Nephritis in Children

  • Perspective
  • Published:
Indian Pediatrics Aims and scope Submit manuscript

Abstract

Lupus nephritis affects 50-75% of all children with systemic lupus erythematosus with a higher prevalence in Asians. Itremains a major contributor to morbidity and mortality in childhood onset lupus. Proliferativelupus nephritis (class III and class IV) warrants aggressive treatment to prevent progression to end stage renal disease. Newerimmunosuppressive agents available in the last decade offer more options to treat lupus nephritis. Despiteguidelines from professional bodies, there remains a lack of consensus on the treatment of refractory disease and duration of maintenance therapy. Wereview the treatment options for pediatric patients with lupus nephritis based on studies and published guidelines in the last decade, and highlight opportunities for continued improvement in care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol. 2010;6:538–46.

    Article  CAS  Google Scholar 

  2. Levy DM, Kamphuis S. Systemic lupus erythematosus in children and adolescents. Pediatr Clin North Am. 2012;59:345–64.

    Article  Google Scholar 

  3. Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: A longitudinal study. J Pediatr. 2008; 152:550–6.

    Article  Google Scholar 

  4. Dooley MA, Aranow C, Ginzler EM. Review of ACR renal criteria in systemic lupus erythematosus. Lupus. 2004; 13:857–60.

    Article  CAS  Google Scholar 

  5. Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017; 12:825–35.

    Article  Google Scholar 

  6. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JHM, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ ERA-EDTA) Recommendations for the Management of Adult and Paediatric Lupus Nephritis. Ann Rheum Dis. 2012;71:1771–82.

    Article  CAS  Google Scholar 

  7. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis. Arthritis Care Res. 2012; 64:797–808.

    Article  Google Scholar 

  8. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004; 65:521–30.

    Article  Google Scholar 

  9. Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. Revision of the International Society of Nephrology/Renal Pathology Society Classification for Lupus Nephritis: Clarification of Definitions, and Modified National Institutes of Health Activity and Chronicity Indices. Kidney Int. 2018;93:789–96.

    Article  Google Scholar 

  10. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012; 2:139–274.

    Article  Google Scholar 

  11. Groot N, de Graeff N, Marks SD, Brogan P, Avcin T, Bader-Meunier B, et al. European Evidence-based Recommendations for the Diagnosis and Treatment of Childhood-onset Lupus Nephritis: the SHARE Initiative. Ann Rheum Dis. 2017; 76:1965–73.

    Article  CAS  Google Scholar 

  12. Bennett M, Brunner HI. Biomarkers and updates on pediatrics lupus nephritis. Rheum Dis Clin North Am. 2013;39:833–53.

    Article  Google Scholar 

  13. Mina R, von Scheven E, Ardoin SP, Eberhard BA, Punaro M, Ilowite N, et al. Consensus Treatment Plans for Induction Therapy of Newly Diagnosed Proliferative Lupus Nephritis in Juvenile Systemic Lupus Erythematosus. Arthritis Care Res. 2012; 64:375–83.

    Article  Google Scholar 

  14. Mendonca S, Gupta D, Ali S, Gupta P. Mycophenolate mofetil or cyclophosphamide in indian patients with lupus nephritis: Which is better? A single-center experience. Saudi J Kidney Dis Transplant. 2017;28:1069–77.

    Article  Google Scholar 

  15. Sahay M, Saivani Y, Ismal K, Vali PS. Mycophenolate versus clophosphamide for lupus nephritis. Indian J Nephrol. 2018;28:35–40.

    Article  CAS  Google Scholar 

  16. Rathi M, Sharma A. Mycophenolate or cyclophosphamide in lupus nephritis: Which one to use in Indian patients? Indian J Nephrol. 2018;28:99–100.

    Article  Google Scholar 

  17. Basu B, Roy B, Babu BG. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Pediatr Nephrol. 2017; 32:1013–21.

    Article  Google Scholar 

  18. Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, et al. Multitarget therapy for induction treatment of lupus nephritis: A randomized trial. Ann Intern Med. 2015;162:18–26.

    Article  Google Scholar 

  19. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012; 64:1215–26.

    Article  CAS  Google Scholar 

  20. Weidenbusch M, Römmele C, Schröttle A, Anders H-J. Beyondthe LUNAR trial. Efficacyof rituximab in refractory lupus nephritis. Nephrol Dial Transplant. 2013; 28:106–11.

    Article  CAS  Google Scholar 

  21. Almaani S, Rovin BH. B-cell therapy in lupus nephritis: An overview. Nephrol Dial Transplant. 2019;34:22–9.

    Article  CAS  Google Scholar 

  22. Ostensen M, Villiger PM. Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Lupus. 2001;10:135–9.

    Article  CAS  Google Scholar 

  23. Grootscholten C, Berden JHM. Discontinuation of immunosuppression in proliferative lupus nephritis: Is it possible? Nephrol Dial Transplant. 2006;21:1465–9.

    Article  Google Scholar 

  24. George J, Sankaramangalam KP, Sinha A, Hari P, Dinda AK, Bagga A. Lupus nephritis in Indian children: Flares and refractory illness. Indian Pediatr. 2018; 55:478–81.

    Article  Google Scholar 

  25. Contreras G, Victoriano P, Baudouin L, Oliver L, Elaine T, Patricia O, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350:971–980.

    Article  CAS  Google Scholar 

  26. Moroni G, Gallelli B, Quaglini S, Banfi G, Rivolta E, Messa P, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant. 2006;21:1541–8.

    Article  CAS  Google Scholar 

  27. Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN nephritis trial. Ann Rheum Dis. 2010;69:2083–9.

    Article  CAS  Google Scholar 

  28. Tian SY, Feldman BM, Beyene J, Brown PE, Uleryk EM, Silverman ED. Immunosuppressive therapies for the maintenance treatment of proliferative lupus nephritis: A systematic review and network metaanalysis. J Rheumatol. 2015; 42:1392–400.

    Article  CAS  Google Scholar 

  29. Palmer SC, Tunnicliffe DJ, Singh-Grewal D, Mavridis D, Tonelli M, Johnson DW, et al. Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: A network meta-analysis of randomized trials. Am J Kidney Dis. 2017;70:324–36.

    Article  Google Scholar 

  30. Zhang H, Liu Z, Zhou M, Liu Z, Chen J, Xing C, et al. Multitarget therapy for maintenance treatment of lupus nephritis. J Am Soc Nephrol. 2017;28:3671–8.

    Article  CAS  Google Scholar 

  31. Aptekar RG, Decker JL, Steinberg AD. Exacerbation of SLE nephritis after cyclophosphamide withdrawal. N Engl J Med. 1972;286:1159–60.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Nephrology Perelman School of Medicine, University of Pennsylvania, Children’s Hospital of Philadelphia, Philadelphia, PA, 19104, USA

    Rebecca Scobell

  2. Clinical Pediatrics, Perelman School of Medicine, University of Pennsylvania, Children’s Hospital of Philadelphia, Philadelphia, PA, 19104, USA

    Madhura Pradhan

Authors
  1. Rebecca Scobell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Madhura Pradhan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Madhura Pradhan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Scobell, R., Pradhan, M. Management of Lupus Nephritis in Children. Indian Pediatr 57, 401–406 (2020). https://doi.org/10.1007/s13312-020-1811-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13312-020-1811-0

Keywords

Search

Navigation